Pharming Group NV - Asset Resilience Ratio
Pharming Group NV (PHARM) has an Asset Resilience Ratio of 7.13% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Pharming Group NV's Asset Resilience Ratio has changed over time. Check PHARM capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Pharming Group NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Pharming Group NV market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €33.80 Million | 7.13% |
| Total Liquid Assets | €33.80 Million | 7.13% |
Asset Resilience Insights
- Limited Liquidity: Pharming Group NV maintains only 7.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pharming Group NV Industry Peers by Asset Resilience Ratio
Compare Pharming Group NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Pharming Group NV (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Pharming Group NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 28.18% | €109.03 Million ≈ $127.47 Million |
€386.88 Million ≈ $452.30 Million |
-4.03pp |
| 2023-12-31 | 32.21% | €137.31 Million ≈ $160.53 Million |
€426.34 Million ≈ $498.44 Million |
-- |
| 2022-12-31 | 0.00% | €0.00 ≈ $0.00 |
€425.80 Million ≈ $497.80 Million |
-- |
| 2019-12-31 | -0.26% | €-661.91K ≈ $-773.84K |
€255.63 Million ≈ $298.86 Million |
-5.84pp |
| 2008-12-31 | 5.59% | €5.22 Million ≈ $6.10 Million |
€93.40 Million ≈ $109.20 Million |
-11.30pp |
| 2005-12-31 | 16.88% | €6.92 Million ≈ $8.09 Million |
€40.96 Million ≈ $47.89 Million |
-- |
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more